<?xml version='1.0' encoding='utf-8'?>
<document id="30227099"><sentence text="An Innovative, Collaborative, and Strategic Approach to Proactively Evaluate and Update Drug Interactions Based on Prescribing Information of Newly Approved Medicinal Products." /><sentence text="Drug-drug interaction (DDIs) are evaluated using pharmacokinetic (PK) simulation models, clinical studies, and scientific publications throughout drug development" /><sentence text=" DDIs with Norvir (ritonavir) and combination products (eg, Kaletra [lopinavir/ritonavir]) containing ritonavir as a PK enhancer are relevant, because these drugs could affect exposures of CYP3A4 substrates"><entity charOffset="11-17" id="DDI-PubMed.30227099.s3.e0" text="Norvir" /><entity charOffset="19-28" id="DDI-PubMed.30227099.s3.e1" text="ritonavir" /><entity charOffset="102-111" id="DDI-PubMed.30227099.s3.e2" text="ritonavir" /><pair ddi="false" e1="DDI-PubMed.30227099.s3.e0" e2="DDI-PubMed.30227099.s3.e0" /><pair ddi="false" e1="DDI-PubMed.30227099.s3.e0" e2="DDI-PubMed.30227099.s3.e1" /><pair ddi="false" e1="DDI-PubMed.30227099.s3.e0" e2="DDI-PubMed.30227099.s3.e2" /><pair ddi="false" e1="DDI-PubMed.30227099.s3.e1" e2="DDI-PubMed.30227099.s3.e1" /><pair ddi="false" e1="DDI-PubMed.30227099.s3.e1" e2="DDI-PubMed.30227099.s3.e2" /></sentence><sentence text=" Application of algorithms proactively identified recently approved drugs, which potentially cause adverse outcomes when given with drugs containing ritonavir"><entity charOffset="149-158" id="DDI-PubMed.30227099.s4.e0" text="ritonavir" /></sentence><sentence text="" /><sentence text="An evidence-based medicine technology platform was used to identify newly approved products" /><sentence text=" PK-related information from the products' prescribing information was reviewed to identify DDIs with ritonavir"><entity charOffset="102-111" id="DDI-PubMed.30227099.s7.e0" text="ritonavir" /></sentence><sentence text=" Algorithms were used to further evaluate PK, clinical, and postmarketing information pertinent to the interaction to determine if prescribing information required revision" /><sentence text="" /><sentence text="From January 1, 2014, through December 31, 2015, 39 newly approved drugs were identified as having potential interactions with Norvir and/or Kaletra" /><sentence text=" Ten drugs were excluded, 19 drugs went through initial screening, and 10 drugs underwent in-depth algorithm-based analyses for DDIs" /><sentence text=" No changes to prescribing information for Norvir or Kaletra were recommended from evaluation of the DDIs" /><sentence text=" Regulatory concurrence with AbbVie decisions was 93" /><sentence text="1% (27/29, 93" /><sentence text="1%); in 6" /><sentence text="9% (2/29, 6" /><sentence text="9%) of the evaluated interactions, at least 1 local regulatory authority disagreed with recommendations, requiring label changes to incorporate the DDI information" /><sentence text="" /><sentence text="This proactive algorithmic approach identifies and complements existing methods used to detect DDIs with newly approved products" /><sentence text=" Additionally, this approach facilitates timely communication of risks to patients and healthcare providers via label revisions, publications, or other regulatory communications" /><sentence text="" /></document>